Form 4: Ionis Pharmaceuticals Executive Sells Shares Under 10b5-1 Trading Plan
SEC Form 4
Eric Swayze, EVP of Research at Ionis Pharmaceuticals, sold 1,194 shares of common stock at a weighted average price of $37.921 per share under a pre-arranged 10b5-1 trading plan.
Summary
- Eric Swayze, an Executive Vice President at Ionis Pharmaceuticals, sold 1,194 shares of the company's common stock.
- The sale occurred on November 12, 2024, at a weighted average price of $37.921 per share.
- The shares were sold under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2024.
- The sale was executed in multiple transactions with prices ranging from $37.90 to $37.95.
- Following the transaction, Mr. Swayze directly owns 33,713 shares and indirectly owns 157 shares through his son.
Sentiment
Score: 5
Explanation: The document is a routine disclosure of an insider stock sale under a pre-arranged trading plan. It does not indicate any positive or negative sentiment about the company's performance or future prospects.
Industry Context
This is a routine disclosure of an insider stock sale under a pre-arranged trading plan, which is a common practice among corporate executives to avoid accusations of insider trading. It does not indicate any specific trend or issue within the company or the broader industry.
Comparison to Industry Standards
- The use of 10b5-1 trading plans is a standard practice for executives at publicly traded companies like Ionis Pharmaceuticals to manage their personal finances while avoiding potential insider trading issues.
- Similar transactions are regularly reported by executives at comparable biotech companies, such as Alnylam Pharmaceuticals and Biogen, as part of their routine financial activities.
Stakeholder Impact
- The stock sale by an executive may have a minor impact on shareholder sentiment, but it is unlikely to significantly affect the company's overall valuation given the small number of shares sold and the pre-planned nature of the transaction.
Key Dates
| Date | Description |
|---|---|
| 08/14/2024 | Date the 10b5-1 trading plan was adopted by Eric Swayze. |
| 11/12/2024 | Date of the stock sale transaction. |
| 11/13/2024 | Date the Form 4 was signed. |
Keywords
Ionis Pharmaceuticals, insider trading, stock sale, Rule 10b5-1, executive, Eric Swayze, IONS
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.